Loading...

PMCB PHARMACYTE BIOTECH INC Delisting Actions 8-K Filing

PHRM

PMCB

PHARMACYTE BIOTECH INC

(PMCB)

2025 8-K

Annual Meeting Summary

Nasdaq Compliance Notice

Amendment Update

Stockholder Meeting Update

Investment Agreement

Stock Offering Details

Accountant Change

Acquisition Agreement

Annual Meeting Voting Results

Grants to Interim CEO and CFO

Entry into Material Definit...

Accountant Change

Resignation of Auditor

Reorganizations

Private Placement

Share Repurchase Program

External Links:

On December 1, 2025, PharmaCyte Biotech, Inc. received a notice from Nasdaq indicating it is not meeting the minimum bid price requirement of $1.00 per share, following a 30-day closing bid price assessment. The company has until June 1, 2026, to regain compliance to avoid potential delisting.

AI Assistant

PHARMACYTE BIOTECH INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.